BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/II Open-Label Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Dabrafenib (Primary) ; Hydroxychloroquine (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BAMM
Most Recent Events
- 12 Jan 2022 Primary endpoint has not been met. (Phase 2: To assess the clinical efficacy of HCQ+D+T by 1 year PFS rate.)
- 12 Jan 2022 Status has been changed to discontinued, as per Results published in the Clinical Cancer Research
- 12 Jan 2022 Results published in the Clinical Cancer Research